Evidence map›Paper›PMID 35681673›Full record

ArticleCancers2022

Dyslipidemia in Children Treated with a BRAF Inhibitor for Low-Grade Gliomas: A New Side Effect?

Marco Crocco, Antonio Verrico, Claudia Milanaccio, Gianluca Piccolo, Patrizia De Marco, Gabriele Gaggero, Valentina Iurilli, Sonia Di Profio, Federica Malerba, Marta Panciroli and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Resistance mechanisms in BRAFFrontiers in oncology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Marco CroccoNeuroncology Unit, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy.ORCID 0000-0001-7277-4767
Antonio VerricoNeuroncology Unit, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy.ORCID 0000-0002-4648-4384
Claudia MilanaccioNeuroncology Unit, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy.
Gianluca PiccoloNeuroncology Unit, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy.ORCID 0000-0003-2815-6288
Patrizia De MarcoUOC Genetica Medica, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy.
Gabriele GaggeroDepartment of Clinical Pathology, IRCCS Ospedale Policlinico San Martino, 16132 Genova, Italy.
Valentina IurilliPharmacy Unit, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy.ORCID 0000-0001-6280-2912
Sonia Di ProfioClinical Psychology, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy.ORCID 0000-0001-7035-2712
Federica MalerbaDepartment of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, 16132 Genova, Italy.ORCID 0000-0002-9105-0630
Marta PanciroliDepartment of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, 16132 Genova, Italy.
Paolo GiordanoDepartment of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, 16132 Genova, Italy.
Maria Grazia CalevoEpidemiology and Biostatistics Unit, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy.
Emilio CasaliniDepartment of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, 16132 Genova, Italy.
Natascia Di IorgiDepartment of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genova, 16132 Genova, Italy.
Maria Luisa GarrèNeuroncology Unit, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy.
Istituto Giannina Gaslini · ITUniversity of Genoa · ITOspedale Policlinico San Martino · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BRAF inhibitors, in recent years, have played a central role in the disease control of unresectable BRAF-mutated pediatric low-grade gliomas (LGGs). The aim of the study was to investigate the acute and long-term effects of vemurafenib on the lipid metabolism in children treated for an LGG. In our cohort, children treated with vemurafenib (

Indexed as

BRAFbrain tumorcholesteroldyslipidemialipid metabolismlow grade gliomatriglyceridesvemurafenib

Identifiers

PMID35681673
PMCPMC9179293
OpenAlexW4281916757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.